A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

NCT02518958 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumor
Lymphoma

Interventions

DRUG: RRx-001
DRUG: Nivolumab

Sponsor

EpicentRx, Inc.